LV untwisting was calculated as the percentage difference between peak twisting and untwisting at MVO (%dpTw-UtwMVO), at peak (%dpTw-UtwPEF) and end of early LV diastolic filling (%dpTw-UtwEDF) (c) Flow mediated dilatation (FMD) of the brachial artery an

10 ± 3 m/s), MDA (02 [05-25] vs. 08 [03-28] nM/L) and NT-proBNP (p < 05) in parallel with an increase in GLS (- 15 ± 3 vs. - 16 ± 2), GLSR (07 ± 0 vs. 09 ± 0), pUtwVel (- 97 ± 49 vs. - 112 ± 52°, p < 05), %dpTw-UtwMVO (31 ± 10 vs. 40 ± 14), %dpTw-UtwPEF (43 ± 19 vs.

53 ± 22) and FMD% (8 ± 3 vs. 13 ± 6, p < 01). There were no statistically significant differences of the measured markers in subjects that received metformin except for an improvement in FMD. In all subjects, PCs levels at baseline were negatively related to the difference of GLS (r = - 03) post-treatment and the difference of MDA was associated with the difference of PWV (r = 02) (p < 05 for all associations) after 6-month CONCLUSIONS: Six-month treatment with liraglutide improves arterial stiffness, LV myocardial strain, LV twisting and untwisting and NT-proBNP by reducing oxidative stress in subjects with newly diagnosed T2DM. ClinicalTrials.gov 10080/09546634021882658. Epub 2021 May 3.

Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and BACKGROUND: Psoriasis usually accompanies comorbidities such as type 2 diabetes, obesity, and cardiovascular disease. It has been proposed that glucagon-like peptide-1 receptor (GLP-1R) agonists used in the treatment of patients with type 2 diabetes may also improve psoriasis. However,  glipizide side effects  of patients in every OBJECTIVES: We carried out a meta-analysis to evaluate whether GLP-1R is effective for the treatment of plaque psoriasis with type 2 diabetes.METHODS: A search of PubMed, Ovid Embase, the Cochrane Library for controlled trials was done from inception to June 20th, 2020. Published trials that included psoriasis patients with type 2 diabetes, the Psoriasis Area and Severity Index (PASI) of treated by GLP-1R before and after. All statistical analyses were conducted using the Stata 15 (Stata Corporation, College RESULTS: There were 4 trials involving 32 patients. Patients treated by GLP-1R after showed significantly lower PASI (SMD: -432, 95% CI: -711 to -153, p = 1), lower fasting plasma glucose than treated before (SMD: -041, 95% CI: -079 to -004, p = 48).

There was no significant difference in Body Mass Index (BMI), Dermatology Life Quality Index (DLQI), and glycated hemoglobin (HbA1c) between treated by GLP-1R after and before.CONCLUSIONS: GLP-1rA, liraglutide, therapy can reduce psoriasis who had concomitant type 2 diabetes severity, but may independently of changes in weight Hearing protection and damage mitigation in Chinchillas exposed to repeated Repeated exposures to blast overpressure (BOP) introduce hearing complaints in military service members even with the use of hearing protection devices (HPDs). Although  Pancreatic hormones and other blood sugar regulating drugs  and animal studies have been performed to investigate the damage formation mechanism of blast-induced hearing damage, there is still a lack of understanding and therapeutic solutions, especially for HPD-protected ears. Recent studies revealed the potential therapeutic function of liraglutide, a glucagon-like peptide-1 receptor agonist, to facilitate post-blast hearing restoration in chinchillas. This study is a continuation and summary of the previous studies performed by Jiang et al. (2021, 2022) to investigate the damage mitigation function of liraglutide treatment in chinchillas with open and protected ears after repeated low-intensity blast exposures within 28 days of observation. Chinchillas were divided into six experimental groups: pre-blast treatment, post-blast treatment, and blast control with ears open or protected by earplug (EP).

All animals were exposed to six consecutive blasts at the level of 3-5 psi (21-35 kPa) on Day 1. Hearing function tests including auditory brainstem response (ABR), distortion product otoacoustic emission (DPOAE), and middle latency response (MLR) were performed on Day 1 (pre- and post-blast) and Days 4, 7, 14, and 28 after blast exposure. Results indicated that the damage mitigation function of the liraglutide treatment in the open-ear chinchillas was reflected by the significantly lower ABR threshold shifts in the drug treatment groups than in the blast controls. In EP groups, the higher ABR wave I/V ratio and lower MLR amplitude observed in the drug-treated chinchillas suggested that the post-blast hyperactivities in the auditory system might be potentially ameliorated by the liraglutide treatment. The 28-day-long experiment showed the effect of liraglutide treatment increased with time in both open and EP groups. This study demonstrated that the use of HPDs prevented the blast-induced complications in the middle ear and reduced the damage caused in the central auditory system.